SCHEMBL8516571

SCHEMBL8516571

CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCN(Cc4cc(Cl)ccc4-c4ccccc4)CC3)cc2)cc1[N+](=O)[O-]

nearest known ligand 0.89

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
BCL2L1 Q07817 20/20 0.89
BCL2 P10415 11/20 0.89
MDM4 O15151 1/20 0.89
BCL2L11 O43521 1/20 0.89
TP53 P04637 1/20 0.89
BID P55957 1/20 0.89
BAX Q07812 1/20 0.89
MCL1 Q07820 1/20 0.89
ASPH Q12797 1/20 0.89
BECN1 Q14457 1/20 0.89
BAK1 Q16611 1/20 0.89
BCL2L2 Q92843 1/20 0.89
BAD Q92934 1/20 0.89
BBC3 Q9BXH1 1/20 0.89

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3426272 1.00 BCL2L1 (0.89) BCL2L1BCL2MDM4BCL2L11TP53
SCHEMBL26648001 0.95 BCL2L1 (0.90) BCL2L1BCL2MDM4BCL2L11TP53
SCHEMBL31450804 0.95 BCL2L1 (0.90) BCL2L1BCL2MDM4BCL2L11TP53
SCHEMBL26648832 0.95 BCL2L1 (0.90) BCL2L1BCL2MDM4BCL2L11TP53
Abt 737 SCHEMBL1541072 0.94 BCL2L1 (1.00) BCL2L1BCL2MDM4BCL2L11TP53
Abt 737 SCHEMBL170470 0.94 BCL2L1 (1.00) BCL2L1BCL2MDM4BCL2L11TP53
Abt 737 SCHEMBL29355185 0.94 BCL2L1 (1.00) BCL2L1BCL2MDM4BCL2L11TP53
Abt 737 SCHEMBL158942 0.94 BCL2L1 (1.00) BCL2L1BCL2MDM4BCL2L11TP53
SCHEMBL1541099 0.94 BCL2L1 (0.88) BCL2L1BCL2MDM4BCL2L11TP53
SCHEMBL26647885 0.94 BCL2L1 (0.88) BCL2L1BCL2MDM4BCL2L11TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3442584-A1 COMBINATIONS OF PBD-BASED ANTIBODY DRUG CONJUGATES WITH BCL-2 INHIBITORS Seattle Genetics, Inc. (US) 2019-02-20 EP disclosed
WO-2017160954-A1 COMBINATIONS OF PBD-BASED ANTIBODY DRUG CONJUGATES WITH BCL-2 INHIBITORS SEATTLE GENETICS, INC. (US) 2017-09-21 WO disclosed
WO-2016079067-A1 COMPOUNDS TARGETING THE BFL-1 ANTI-APOPTOTIC PROTEIN AND USES THEREOF FOR THE TREATMENT OF CANCER INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2016-05-26 WO disclosed
EP-2643322-A1 SALTS AND CRYSTALLINE FORMS OF AN APOPTOSIS-INDUCING AGENT Abbvie Inc. (US) 2013-10-02 EP disclosed
WO-2012071336-A1 SALTS AND CRYSTALLINE FORMS OF AN APOPTOSIS-INDUCING AGENT ABBOTT LABORATORIES (US) 2012-05-31 WO disclosed